After six months of looking for a partner for its inflammation research programs located at the former Synergen facilities in Boulder, Colo., Amgen Inc. has decided to stop looking. Boulder employees now will seek funding for a new company to house the discovery research efforts abandoned by AMGN. But if the biotech giant itself could not find takers, they may be fighting an uphill battle.

AMGN (Thousand Oaks, Calif.) would not disclose specifics of its search for a partner to help fund development expenses at Boulder (see BioCentury, Sept. 8, 1997). "It's basically a matter of having spent six months looking for a partnership and being unable to find someone who sufficiently valued the upside and was willing to invest sufficient resources to fund the program," said spokesperson David Kaye.